News headlines about AtriCure (NASDAQ:ATRC) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AtriCure earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 46.1878034044571 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
ATRC has been the subject of a number of research analyst reports. BidaskClub raised shares of AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, March 17th. Piper Jaffray Companies reissued a “buy” rating and set a $24.00 target price on shares of AtriCure in a research report on Sunday, December 10th. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of AtriCure in a research report on Tuesday, February 27th. TheStreet lowered shares of AtriCure from a “c-” rating to a “d+” rating in a research report on Wednesday, November 29th. Finally, ValuEngine raised shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. AtriCure has a consensus rating of “Buy” and a consensus target price of $24.80.
AtriCure (NASDAQ:ATRC) opened at $19.77 on Friday. The firm has a market cap of $693.63, a price-to-earnings ratio of -23.82 and a beta of 0.30. The company has a current ratio of 2.58, a quick ratio of 1.87 and a debt-to-equity ratio of 0.23. AtriCure has a 52-week low of $14.88 and a 52-week high of $25.18.
In other news, SVP Justin J. Noznesky sold 4,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $17.03, for a total transaction of $68,120.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. The disclosure for this sale can be found here. Insiders own 10.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3293500/atricure-atrc-receives-daily-news-impact-rating-of-0-17.html.
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.